Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical gonatoxin proof-of-concept study for chemotherapy-induced peripheral neuropathy
RBR-3y5dtqtRecruiting
- Sponsor
- Oncoclínicas
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of PSP NEURO SERUM in chemotherapy-induced peripheral neuropathy (CIPN) (2 cohorts), sponsored by Oncoclínicas. Primary endpoints: Response rate in Cohort 1 during Phase 1, Response rate in Cohort 2 during Phase 1 and 2 more. Started Sep 2020; status: recruiting.
02
Drugs
PSP NEURO SERUM
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on RBR-3y5dtqt.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-3y5dtqt.